Medicine and research reference
Retatrutide
Selected human research on a triple-receptor agonist, including trial limits, adverse events and U.S. status.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Identity and mechanism
Retatrutide, also called LY3437943, activates GIP, GLP-1 and glucagon receptors. It is a distinct molecule; evidence for semaglutide or tirzepatide does not establish its clinical effects.
Sources: Jastreboff and colleagues, New England Journal of Medicine; indexed by Europe PMC
A controlled human trial
A 2023 phase 2 trial enrolled 338 adults with obesity or overweight and a related condition. The study compared retatrutide with placebo over 48 weeks and found greater average weight reduction in the active-treatment groups. Eli Lilly funded it. Its size and duration limit conclusions about uncommon harms and long-term outcomes; this selected trial is not the whole development programme.
Sources: Jastreboff and colleagues, New England Journal of Medicine; indexed by Europe PMC
Adverse effects and status
Gastrointestinal effects were the most common adverse events and varied with study exposure. Heart-rate increases were also observed. The trial assessed retatrutide itself, not a cagrilintide mixture or a supplier’s research powder.
Sources: Jastreboff and colleagues, New England Journal of Medicine; indexed by Europe PMC
FDA’s current reference identifies retatrutide as outside FDA-approved medicines and warns about unapproved products sold for human use.
Sources: U.S. Food and Drug Administration
Published sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
Jastreboff and colleagues, New England Journal of Medicine; indexed by Europe PMC. Published 26 June 2023 online; accessed 6 September 2026.
Supports: Triple-receptor identity, 338-participant trial, weight outcomes, gastrointestinal effects and heart-rate changes.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
U.S. Food and Drug Administration. Current FDA reference; accessed 6 September 2026.
Supports: U.S. status of retatrutide and cagrilintide and concerns about unapproved products sold for human use.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.